Storia in 1 fonti

Alteogen signs deal with Novartis worth up to $3.2 bil. for subcutaneous formulations - The Korea Times

Korean biotechnology company Alteogen Inc. said Wednesday that it signed an option and licensing agreement with Novartis AG worth up to 4.4 trillio...

Raccontata da

koreatimes.co.kr

Timeline cronologica

mercoledì 2 settembre 2026·koreatimes.co.kr
Alteogen signs deal with Novartis worth up to $3.2 bil. for subcutaneous formulations - The Korea Times
Korean biotechnology company Alteogen Inc. said Wednesday that it signed an option and licensing agreement with Novartis AG worth up to 4.4 trillio...